Skip to content

Medtronic up on Q2 beat; strong margins tops expectations

August 25, 2020

Medtronic (MDT) Q2 results:

Revenues: $6,507M (-13.2%).

Cardiac & Vascular Group revenues of $2.433B (-12.8%), compared to estimate $1.81B.

Minimally Invasive Therapies Group revenues are $1.8B (-14.2%), vs. consensus of $1.76.

Restorative Therapies Group: $1.712B (-14.9%) compared to expectations of $1.33B; Diabetes Group: $562M (-5.1%).

Adjusted gross margin of 62.1% vs. estimate of 60.5%; Adjusted operating margin 16.5%, consensus 7.2%.

Net Income: $487M (-43.6%); EPS: $0.36 (-43.8%); non-GAAP Net Income: $836M (-50.9%); non-GAAP EPS: $0.62 (-50.8%).

CF Ops: $278M (-81.6%).

Citing COVID-19 uncertainties, the company is not providing formal annual or quarterly financial guidance at this time.

Below is the timeline of the company’s key product approvals in CY2020 till date in key geographies:

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: